PSEN1 and Alzheimer disease: This is an amyloid beta-directed monoclonal antibody, recently approved by the US Food and Drug Administration, that was generally based on the initial genetic findings of APP, PSEN1, and PSEN2 mutations as causes of AD and the subsequent development of the amyloid cascade hypothesis [8].